Septerna, Inc. (SEPN)

Septerna, Inc. experienced significant insider trading activity recently, totaling over $30.9 million in sales across 21 transactions. Key executives and major shareholders, including CEO Jeffrey Finer and Samsara BioCapital, executed planned divestments following the company's latest results financiers. These movements occurred amidst a 5.1% decline in stock value over the preceding ninety-day period.
Ticker: SEPN Exchange: NMS


Loading...
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Septerna, Inc.. Upgrade to see score, net flow, insiders and the full signal context.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
3.5
Finer Jeffrey Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
25.98
Quantity 25,732 -43.5%
Value US$360,003
3.5
Finer Jeffrey Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
190.69
Quantity 87,137 +43.5%
Value US$4,795,563
3.5
Finer Jeffrey Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
44.23
Quantity 1,000 -0.3%
Value US$100,000
3.5
Finer Jeffrey Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
43.10
Quantity 1,000 -0.6%
Value US$100,000
3.5
Finer Jeffrey Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
42.09
Quantity 1,000 -0.7%
Value US$100,000
1.7
Samsara BioCapital, L.P. Shareholder
Transaction date
Proposed sale
Price
48.56
Quantity 1,000
Value US$100,000
3.5
JEFFREY FINER Director; Officer Executive Director
Transaction date
Proposed sale
Price
48.56
Quantity 1,000
Value US$100,000
2.8
Ezekowitz Alan Non-Executive Director
Transaction date
Planned sale
Price
51.90
Quantity 1,000 -2.9%
Value US$100,000
2.8
Ezekowitz Alan Non-Executive Director
Transaction date
Planned sale
Price
50.90
Quantity 1,000 -5.2%
Value US$100,000
2.8
Ezekowitz Alan Non-Executive Director
Transaction date
Planned sale
Price
49.65
Quantity 1,000 -9.7%
Value US$100,000
2.8
Ezekowitz Alan Non-Executive Director
Transaction date
Planned sale
Price
48.70
Quantity 1,000 -42.4%
Value US$100,000
2.8
Ezekowitz Alan Non-Executive Director
Transaction date
Planned sale
Price
47.78
Quantity 1,000 -23.5%
Value US$100,000
2.8
Ezekowitz Alan Non-Executive Director
Transaction date
Planned sale
Price
47.01
Quantity 1,000 -11.9%
Value US$100,000
2.8
Ezekowitz Alan Non-Executive Director
Transaction date
Planned sale
Price
46.01
Quantity 1,000 -5.9%
Value US$100,000
2.8
ALAN EZEKOWITZ Director Non-Executive Director
Transaction date
Proposed sale
Price
52.34
Quantity 1,000
Value US$100,000
Bhatt Elizabeth President and COO Officer
Transaction date
Planned sale
Price
37.61
Quantity 2,906 -1.6%
Value US$109,307
Bhatt Elizabeth President and COO Officer
Transaction date
Planned sale
Price
36.87
Quantity 1,094 -0.6%
Value US$40,337
DANIEL LONG Officer Officer
Transaction date
Proposed sale
Price
39.13
Quantity 10,001
Value US$391,339
SAMIRA SHAIKHLY Officer Officer
Transaction date
Proposed sale
Price
39.13
Quantity 12,592
Value US$492,725
Long Daniel D. SVP, Drug Discovery Officer
Transaction date
Planned sale
Price
37.83
Quantity 3,333 -3.3%
Value US$126,078
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Sale
Price
42.50
Quantity 746,500 -50.7%
Value US$31,726,250
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Sale
Price
42.50
Quantity 746,500 -13.5%
Value US$31,726,250
Transaction date
Proposed sale
Price
48.19
Quantity 746,500
Value US$35,973,835
3.2
Third Rock Ventures V, L.P. 10% Stockholder Large shareholder
Transaction date
Proposed sale
Price
51.00
Quantity 147,200
Value US$7,507,200
Bhatt Elizabeth President and COO Officer
Transaction date
Planned sale
Price
44.00
Quantity 25,000 -12.5%
Value US$1,100,000
ELIZABETH P. BHATT Officer Officer
Transaction date
Proposed sale
Price
38.85
Quantity 29,000
Value US$1,126,650
Long Daniel D. SVP, Drug Discovery Officer
Transaction date
Planned sale
Price
34.68
Quantity 2,334 -2.4%
Value US$80,944
Long Daniel D. SVP, Drug Discovery Officer
Transaction date
Planned sale
Price
33.98
Quantity 1,000 -1.0%
Value US$33,976
Bhatt Elizabeth President and COO Officer
Transaction date
Planned sale
Price
33.99
Quantity 4,000 -2.2%
Value US$135,974
ELIZABETH P. BHATT Officer Officer
Transaction date
Proposed sale
Price
34.54
Quantity 4,000
Value US$138,160
Long Daniel D. SVP, Drug Discovery Officer
Transaction date
Planned sale
Price
34.81
Quantity 1,233 -1.3%
Value US$42,926
Long Daniel D. SVP, Drug Discovery Officer
Transaction date
Planned sale
Price
34.10
Quantity 2,100 -2.1%
Value US$71,602
Shaikhly Samira Chief People Officer Officer
Transaction date
Planned sale
Price
35.18
Quantity 2,178 -73.3%
Value US$76,622
JAE KIM Officer Officer
Transaction date
Proposed sale
Price
36.61
Quantity 2,438
Value US$89,243
Long Daniel D. SVP, Drug Discovery Officer
Transaction date
Planned sale
Price
35.97
Quantity 7,000 -6.8%
Value US$251,781
Long Daniel D. SVP, Drug Discovery Officer
Transaction date
Planned sale
Price
35.10
Quantity 8,000 -7.2%
Value US$280,801
DANIEL LONG Officer Officer
Transaction date
Proposed sale
Price
36.17
Quantity 25,000
Value US$904,250
DANIEL LONG Officer Officer
Transaction date
Proposed sale
Price
36.17
Quantity 25,000
Value US$904,250
JAE KIM Officer Officer
Transaction date
Proposed sale
Price
35.26
Quantity 94,339
Value US$3,326,120
JAE KIM Officer Officer
Transaction date
Proposed sale
Price
35.26
Quantity 94,339
Value US$3,326,120
Shaikhly Samira Chief People Officer Officer
Transaction date
Planned sale
Price
35.08
Quantity 6,250 -88.7%
Value US$219,224
SAMIRA SHAIKHLY Officer Officer
Transaction date
Proposed sale
Price
34.03
Quantity 8,428
Value US$286,805
Shaikhly Samira Chief People Officer Officer
Transaction date
Planned sale
Price
29.66
Quantity 2,889 -78.5%
Value US$85,696
Shaikhly Samira Chief People Officer Officer
Transaction date
Planned sale
Price
28.79
Quantity 1,346 -26.8%
Value US$38,755
Shaikhly Samira Chief People Officer Officer
Transaction date
Planned sale
Price
27.78
Quantity 1,700 -25.3%
Value US$47,231
Shaikhly Samira Chief People Officer Officer
Transaction date
Planned sale
Price
30.06
Quantity 11,798 -93.7%
Value US$354,656
SAMIRA SHAIKHLY Officer Officer
Transaction date
Proposed sale
Price
28.36
Quantity 11,798
Value US$334,591
Bhatt Elizabeth President and COO Officer
Transaction date
Planned sale
Price
25.86
Quantity 326 -0.2%
Value US$8,431
Bhatt Elizabeth President and COO Officer
Transaction date
Planned sale
Price
25.24
Quantity 1,101 -0.6%
Value US$27,789
Bhatt Elizabeth President and COO Officer
Transaction date
Planned sale
Price
23.76
Quantity 2,573 -1.4%
Value US$61,124
Shaikhly Samira Chief People Officer Officer
Transaction date
Planned sale
Price
28.14
Quantity 66,363 -98.8%
Value US$1,867,342
Shaikhly Samira Chief People Officer Officer
Transaction date
Planned sale
Price
27.51
Quantity 4,090 -5.7%
Value US$112,496
SAMIRA SHAIKHLY Officer Officer
Transaction date
Proposed sale
Price
29.02
Quantity 76,388
Value US$2,216,780
Bhatt Elizabeth President and COO Officer
Transaction date
Planned sale
Price
29.58
Quantity 1,800 -1.0%
Value US$53,250
Bhatt Elizabeth President and COO Officer
Transaction date
Planned sale
Price
28.46
Quantity 2,200 -1.2%
Value US$62,611
ELIZABETH BHATT Officer Officer
Transaction date
Proposed sale
Price
30.30
Quantity 8,000
Value US$242,400
Long Daniel D. SVP, Drug Discovery Officer
Transaction date
Planned sale
Price
18.06
Quantity 3,501 -3.6%
Value US$63,223
DANIEL DAVID LONG Officer Officer
Transaction date
Proposed sale
Price
18.06
Quantity 3,501
Value US$63,223
2.8
Ezekowitz Alan Non-Executive Director
Transaction date
Purchase
Price
6.93
Quantity 13,319 +12.8%
Value US$92,270
2.8
Ezekowitz Alan Non-Executive Director
Transaction date
Purchase
Price
6.00
Quantity 41,355 +65.9%
Value US$248,130
2.8
Ezekowitz Alan Non-Executive Director
Transaction date
Purchase
Price
5.82
Quantity 37,835 +151.9%
Value US$220,260
2.8
Ezekowitz Alan Non-Executive Director
Transaction date
Purchase
Price
6.35
Quantity 7,491 +43.0%
Value US$47,544
3.6
Labrucherie Gil M Chief Financial Officer Officer
Transaction date
Purchase
Price
5.85
Quantity 3,718 +10.2%
Value US$21,750
3.5
Finer Jeffrey CEO and President Executive Director
Transaction date
Purchase
Price
5.80
Quantity 3,000 +0.4%
Value US$17,400
3.5
Finer Jeffrey CEO and President Executive Director
Transaction date
Purchase
Price
5.70
Quantity 4,000 +0.5%
Value US$22,796
3.6
Labrucherie Gil M Chief Financial Officer Officer
Transaction date
Purchase
Price
5.59
Quantity 6,282 +20.9%
Value US$35,116
3.5
Finer Jeffrey CEO and President Executive Director
Transaction date
Purchase
Price
5.68
Quantity 10,000 +1.3%
Value US$56,765
3.6
Labrucherie Gil M Chief Financial Officer Officer
Transaction date
Purchase
Price
5.85
Quantity 5,000 +20.0%
Value US$29,250
3.6
Labrucherie Gil M Chief Financial Officer Officer
Transaction date
Purchase
Price
5.88
Quantity 14,500 +138.1%
Value US$85,234
3.6
Labrucherie Gil M Chief Financial Officer Officer
Transaction date
Purchase
Price
5.51
Quantity 10,500 New position
Value US$57,813
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value
Number of shares Price Value Details
2026-11-16 2026-11-16 PrS Proposed sale

Officer

Officer
17,584
373.33
US$3,562,905
17,584 373.33 US$3,562,905
2026-11-16 2026-11-12 PlS Planned sale

Chief Executive Officer

Executive Director
25,732 -43.5%
25.98
US$360,003
25,732 -43.5% 25.98 US$360,003
2026-11-16 2026-11-12 PlS Planned sale

Chief Executive Officer

Executive Director
87,137 +43.5%
190.69
US$4,795,563
87,137 +43.5% 190.69 US$4,795,563
2026-11-16 2026-11-12 PlS Planned sale

Chief Executive Officer

Executive Director
1,000 -0.3%
44.23
US$100,000
1,000 -0.3% 44.23 US$100,000
2026-11-16 2026-11-12 PlS Planned sale

Chief Executive Officer

Executive Director
1,000 -0.6%
43.10
US$100,000
1,000 -0.6% 43.10 US$100,000
2026-11-16 2026-11-12 PlS Planned sale

Chief Executive Officer

Executive Director
1,000 -0.7%
42.09
US$100,000
1,000 -0.7% 42.09 US$100,000
2026-11-12 2026-11-12 PrS Proposed sale

Shareholder

1,000
48.56
US$100,000
1,000 48.56 US$100,000
2026-11-12 2026-11-12 PrS Proposed sale

Director; Officer

Executive Director
1,000
48.56
US$100,000
1,000 48.56 US$100,000
2026-11-13 2026-11-11 PlS Planned sale Non-Executive Director
1,000 -2.9%
51.90
US$100,000
1,000 -2.9% 51.90 US$100,000
2026-11-13 2026-11-11 PlS Planned sale Non-Executive Director
1,000 -5.2%
50.90
US$100,000
1,000 -5.2% 50.90 US$100,000
2026-11-13 2026-11-11 PlS Planned sale Non-Executive Director
1,000 -9.7%
49.65
US$100,000
1,000 -9.7% 49.65 US$100,000
2026-11-13 2026-11-11 PlS Planned sale Non-Executive Director
1,000 -42.4%
48.70
US$100,000
1,000 -42.4% 48.70 US$100,000
2026-11-13 2026-11-11 PlS Planned sale Non-Executive Director
1,000 -23.5%
47.78
US$100,000
1,000 -23.5% 47.78 US$100,000
2026-11-13 2026-11-11 PlS Planned sale Non-Executive Director
1,000 -11.9%
47.01
US$100,000
1,000 -11.9% 47.01 US$100,000
2026-11-13 2026-11-11 PlS Planned sale Non-Executive Director
1,000 -5.9%
46.01
US$100,000
1,000 -5.9% 46.01 US$100,000
2026-11-12 2026-11-11 PrS Proposed sale

Director

Non-Executive Director
1,000
52.34
US$100,000
1,000 52.34 US$100,000
2026-10-19 2026-10-15 PlS Planned sale

President and COO

Officer
2,906 -1.6%
37.61
US$109,307
2,906 -1.6% 37.61 US$109,307
2026-10-19 2026-10-15 PlS Planned sale

President and COO

Officer
1,094 -0.6%
36.87
US$40,337
1,094 -0.6% 36.87 US$40,337
2026-10-01 2026-10-01 PrS Proposed sale

Officer

Officer
10,001
39.13
US$391,339
10,001 39.13 US$391,339
2026-10-01 2026-10-01 PrS Proposed sale

Officer

Officer
12,592
39.13
US$492,725
12,592 39.13 US$492,725
2026-09-03 2026-09-01 PlS Planned sale

SVP, Drug Discovery

Officer
3,333 -3.3%
37.83
US$126,078
3,333 -3.3% 37.83 US$126,078
2026-08-14 2026-08-12 S Sale Non-Executive Director Large shareholder
746,500 -50.7%
42.50
US$31,726,250
746,500 -50.7% 42.50 US$31,726,250
2026-08-14 2026-08-12 S Sale Non-Executive Director Large shareholder
746,500 -13.5%
42.50
US$31,726,250
746,500 -13.5% 42.50 US$31,726,250
2026-08-12 2026-08-12 PrS Proposed sale

affiliate

746,500
48.19
US$35,973,835
746,500 48.19 US$35,973,835
2026-08-12 2026-08-12 PrS Proposed sale

Affiliate

746,500
48.19
US$35,973,835
746,500 48.19 US$35,973,835
2026-08-12 2026-08-12 PrS Proposed sale

10% Stockholder

Large shareholder
147,200
51.00
US$7,507,200
147,200 51.00 US$7,507,200
2026-08-13 2026-08-11 PlS Planned sale

President and COO

Officer
25,000 -12.5%
44.00
US$1,100,000
25,000 -12.5% 44.00 US$1,100,000
2026-08-11 2026-08-11 PrS Proposed sale

Officer

Officer
29,000
38.85
US$1,126,650
29,000 38.85 US$1,126,650
2026-08-05 2026-08-03 PlS Planned sale

SVP, Drug Discovery

Officer
2,334 -2.4%
34.68
US$80,944
2,334 -2.4% 34.68 US$80,944
2026-08-05 2026-08-03 PlS Planned sale

SVP, Drug Discovery

Officer
1,000 -1.0%
33.98
US$33,976
1,000 -1.0% 33.98 US$33,976
2026-07-17 2026-07-15 PlS Planned sale

President and COO

Officer
4,000 -2.2%
33.99
US$135,974
4,000 -2.2% 33.99 US$135,974
2026-07-15 2026-07-15 PrS Proposed sale

Officer

Officer
4,000
34.54
US$138,160
4,000 34.54 US$138,160
2026-07-02 2026-07-01 PlS Planned sale

SVP, Drug Discovery

Officer
1,233 -1.3%
34.81
US$42,926
1,233 -1.3% 34.81 US$42,926
2026-07-02 2026-07-01 PlS Planned sale

SVP, Drug Discovery

Officer
2,100 -2.1%
34.10
US$71,602
2,100 -2.1% 34.10 US$71,602
2026-06-30 2026-06-29 PlS Planned sale

Chief People Officer

Officer
2,178 -73.3%
35.18
US$76,622
2,178 -73.3% 35.18 US$76,622
2026-06-26 2026-06-26 PrS Proposed sale

Officer

Officer
2,438
36.61
US$89,243
2,438 36.61 US$89,243
2026-06-24 2026-06-22 PlS Planned sale

SVP, Drug Discovery

Officer
7,000 -6.8%
35.97
US$251,781
7,000 -6.8% 35.97 US$251,781
2026-06-24 2026-06-22 PlS Planned sale

SVP, Drug Discovery

Officer
8,000 -7.2%
35.10
US$280,801
8,000 -7.2% 35.10 US$280,801
2026-06-22 2026-06-22 PrS Proposed sale

Officer

Officer
25,000
36.17
US$904,250
25,000 36.17 US$904,250
2026-06-22 2026-06-22 PrS Proposed sale

Officer

Officer
25,000
36.17
US$904,250
25,000 36.17 US$904,250
2026-06-22 2026-06-22 PrS Proposed sale

Officer

Officer
94,339
35.26
US$3,326,120
94,339 35.26 US$3,326,120
2026-06-22 2026-06-22 PrS Proposed sale

Officer

Officer
94,339
35.26
US$3,326,120
94,339 35.26 US$3,326,120
2026-06-16 2026-06-12 PlS Planned sale

Chief People Officer

Officer
6,250 -88.7%
35.08
US$219,224
6,250 -88.7% 35.08 US$219,224
2026-06-12 2026-06-12 PrS Proposed sale

Officer

Officer
8,428
34.03
US$286,805
8,428 34.03 US$286,805
2026-06-03 2026-06-01 PlS Planned sale

Chief People Officer

Officer
2,889 -78.5%
29.66
US$85,696
2,889 -78.5% 29.66 US$85,696
2026-06-03 2026-06-01 PlS Planned sale

Chief People Officer

Officer
1,346 -26.8%
28.79
US$38,755
1,346 -26.8% 28.79 US$38,755
2026-06-03 2026-06-01 PlS Planned sale

Chief People Officer

Officer
1,700 -25.3%
27.78
US$47,231
1,700 -25.3% 27.78 US$47,231
2026-05-28 2026-05-26 PlS Planned sale

Chief People Officer

Officer
11,798 -93.7%
30.06
US$354,656
11,798 -93.7% 30.06 US$354,656
2026-05-26 2026-05-26 PrS Proposed sale

Officer

Officer
11,798
28.36
US$334,591
11,798 28.36 US$334,591
2026-04-17 2026-04-15 PlS Planned sale

President and COO

Officer
326 -0.2%
25.86
US$8,431
326 -0.2% 25.86 US$8,431
2026-04-17 2026-04-15 PlS Planned sale

President and COO

Officer
1,101 -0.6%
25.24
US$27,789
1,101 -0.6% 25.24 US$27,789
2026-04-17 2026-04-15 PlS Planned sale

President and COO

Officer
2,573 -1.4%
23.76
US$61,124
2,573 -1.4% 23.76 US$61,124
2026-03-04 2026-03-02 PlS Planned sale

Chief People Officer

Officer
66,363 -98.8%
28.14
US$1,867,342
66,363 -98.8% 28.14 US$1,867,342
2026-03-04 2026-03-02 PlS Planned sale

Chief People Officer

Officer
4,090 -5.7%
27.51
US$112,496
4,090 -5.7% 27.51 US$112,496
2026-03-02 2026-03-02 PrS Proposed sale

Officer

Officer
76,388
29.02
US$2,216,780
76,388 29.02 US$2,216,780
2026-02-20 2026-02-18 PlS Planned sale

President and COO

Officer
1,800 -1.0%
29.58
US$53,250
1,800 -1.0% 29.58 US$53,250
2026-02-20 2026-02-18 PlS Planned sale

President and COO

Officer
2,200 -1.2%
28.46
US$62,611
2,200 -1.2% 28.46 US$62,611
2026-02-18 2026-02-18 PrS Proposed sale

Officer

Officer
8,000
30.30
US$242,400
8,000 30.30 US$242,400
2025-11-13 2025-11-10 PlS Planned sale

SVP, Drug Discovery

Officer
3,501 -3.6%
18.06
US$63,223
3,501 -3.6% 18.06 US$63,223
2025-11-10 2025-11-10 PrS Proposed sale

Officer

Officer
3,501
18.06
US$63,223
3,501 18.06 US$63,223
2025-03-10 2025-03-07 B Purchase Non-Executive Director
13,319 +12.8%
6.93
US$92,270
13,319 +12.8% 6.93 US$92,270
2025-03-06 2025-03-06 B Purchase Non-Executive Director
41,355 +65.9%
6.00
US$248,130
41,355 +65.9% 6.00 US$248,130
2025-03-06 2025-03-05 B Purchase Non-Executive Director
37,835 +151.9%
5.82
US$220,260
37,835 +151.9% 5.82 US$220,260
2025-03-06 2025-03-04 B Purchase Non-Executive Director
7,491 +43.0%
6.35
US$47,544
7,491 +43.0% 6.35 US$47,544
2025-02-27 2025-02-27 B Purchase

Chief Financial Officer

Officer
3,718 +10.2%
5.85
US$21,750
3,718 +10.2% 5.85 US$21,750
2025-02-27 2025-02-27 B Purchase

CEO and President

Executive Director
3,000 +0.4%
5.80
US$17,400
3,000 +0.4% 5.80 US$17,400
2025-02-27 2025-02-26 B Purchase

CEO and President

Executive Director
4,000 +0.5%
5.70
US$22,796
4,000 +0.5% 5.70 US$22,796
2025-02-27 2025-02-25 B Purchase

Chief Financial Officer

Officer
6,282 +20.9%
5.59
US$35,116
6,282 +20.9% 5.59 US$35,116
2025-02-27 2025-02-25 B Purchase

CEO and President

Executive Director
10,000 +1.3%
5.68
US$56,765
10,000 +1.3% 5.68 US$56,765
2025-02-26 2025-02-24 B Purchase Large shareholder
18,861 +0.4%
6.00
US$113,147
18,861 +0.4% 6.00 US$113,147
2025-02-24 2025-02-21 B Purchase Large shareholder
427,668 +11.4%
5.94
US$2,540,348
427,668 +11.4% 5.94 US$2,540,348
2025-02-21 2025-02-21 B Purchase

Chief Financial Officer

Officer
5,000 +20.0%
5.85
US$29,250
5,000 +20.0% 5.85 US$29,250
2025-02-24 2025-02-20 B Purchase Large shareholder
612,674 +19.4%
5.92
US$3,627,030
612,674 +19.4% 5.92 US$3,627,030
2025-02-21 2025-02-20 B Purchase

Chief Financial Officer

Officer
14,500 +138.1%
5.88
US$85,234
14,500 +138.1% 5.88 US$85,234
2025-02-21 2025-02-19 B Purchase

Chief Financial Officer

Officer
10,500 New position
5.51
US$57,813
10,500 New position 5.51 US$57,813

See older Septerna, Inc. insider trades

Plus unlocks the full transaction history.

See localized pricing at checkout
Unlock Septerna, Inc. history with Plus

Billed monthly · Cancel anytime